Full-Time

Project Manager

Libraries

Updated on 9/3/2026

Twist Bioscience

Twist Bioscience

1,001-5,000 employees

Produces synthetic DNA for research.

Compensation Overview

$99k - $132k/yr

+ Bonus + Equity

Remote in USA + 1 more

More locations: South San Francisco, CA, USA

Hybrid

The role may be fully remote or based in South San Francisco.

Bachelor's

Category
Project & Program Management (1)

Get referred to Twist Bioscience

See people who can refer or advise you

Requirements
  • 2-3 years of relevant work experience in the life sciences or a related field, including more than 2 years in a customer-facing role.
  • A bachelor's degree in Biology, Chemistry, or a related Life Science is required.
  • General knowledge of library fabrication workflows.
  • Experience communicating with customers from inquiry through delivery of services.
  • Understanding of service offerings and the customer workflows they address.
  • Proven ability to work effectively with customers, internal operations, and sales teams.
  • A demonstrated track record of managing projects that meet customer expectations.
  • Ability to follow regulatory and ISO 13485 requirements.
Responsibilities
  • Respond directly to, or direct, incoming inquiries from customers and global sales and support organizations to the appropriate Library Team expertise, provide information from the Library Team, and maintain records.
  • Coordinate and collate detailed library design input from customers and global sales and support teams, ensuring that design data supports customer needs and reflects Library Fabrication Team capabilities.
  • Work with the Library Project Manager and Library Fabrication Teams to collect costing for specific library designs as part of quote preparation.
  • Prepare and distribute quotes for libraries and related business with the Director of the Library Business and Library Project Manager, and maintain an up-to-date database of issued quotations.
  • Collect, collate, and maintain accessible databases of non-disclosure agreements, library quotes, library designs, orders, and shipments.
  • Maintain an accessible list of library work in progress.
  • Maintain accurate and timely records in all systems for reporting on quotes issued, orders placed, orders in progress, and orders shipped.
  • Provide project progress updates to designated customers as agreed.
  • Manage communication between customers and the internal team, providing order-fulfillment details and deliverables.
  • Undertake other ad hoc projects as required.
  • Follow regulatory and ISO 13485 requirements.
Desired Qualifications
  • An advanced degree and/or hands-on laboratory experience is a bonus.

Twist Bioscience designs and manufactures synthetic DNA for biotech, pharmaceutical, and research use. It uses a proprietary platform that rapidly produces custom DNA sequences and a smart algorithm to verify synthesis feasibility before production, with customers submitting requests and receiving DNA, DNA data storage, or NGS services. It differentiates itself by offering high-quality DNA at competitive prices, the ability to handle complex sequences, and an integrated platform with a broad product range for fast delivery. Its goal is to be a reliable, leading supplier of synthetic DNA and genomics tools that accelerates biotech and drug development for a wide range of clients.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2013

Get referred to Twist Bioscience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Twist raised FY2026 revenue guidance to $456–457 million after Q3 revenue hit $118.4 million.
  • AI drug discovery and genomic database demand drove 39% growth in DNA Synthesis and Protein Solutions.
  • Management expects adjusted EBITDA breakeven in Q4 FY2026, improving credibility with investors and recruits.

What critics are saying

  • August 2026’s $250 million offering and prior dilution pressure per-share returns.
  • The $17.05 million securities settlement finalizes November 18, 2026, prolonging governance overhang.
  • Illumina, Thermo Fisher, and synthetic biology peers can compress pricing; manufacturing setbacks threaten relevance.

What makes Twist Bioscience unique

  • Twist’s silicon-based synthesis platform still delivers high-throughput, complex DNA at scale.
  • August 2026 Complex Genes expands into high-GC, repetitive constructs competitors struggle to make.
  • Automated NGS workflows with Volta Labs embed Twist deeper into lab operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 9th, 2026
Twist Bioscience raises $300M at $96/share after hiking 2026 revenue guidance to $457M

Twist Bioscience raised $300 million through a follow-on stock offering at $96 per share in early August 2026. The synthetic biology company simultaneously increased its fiscal 2026 revenue guidance to $456–457 million and reported third-quarter sales of $118.38 million, though it posted a net loss of $35.05 million. The firm is also working to resolve legacy securities litigation through a proposed $17.05 million class-action settlement. Fourth-quarter revenue guidance stands at $123–124 million. Despite the upgraded outlook, analysts remain cautious about Twist's path to profitability. Some project continued losses alongside approximately 15% annual revenue growth. The company's share price rose 26.3% following the announcements, though concerns about ongoing dilution and losses persist.

Microsoft
Aug 4th, 2026
Twist Bioscience launches $250M public stock offering to fund R&D and manufacturing expansion

Twist Bioscience has launched an underwritten public offering of $250 million of common stock. The synthetic biology company has also granted underwriters a 30-day option to purchase up to an additional $37.5 million of shares. All shares in the offering are being sold by Twist Bioscience. The company plans to use the proceeds to fund research and development investments, expand manufacturing capacity, develop product offerings, and support general corporate purposes.

Yahoo Finance
Aug 3rd, 2026
Twist Bioscience raises guidance to $457M as AI drug discovery drives 23% revenue growth

Twist Bioscience reported fiscal Q3 revenue of $118.4 million, up 23% year over year, marking its 14th consecutive quarter of growth. DNA Synthesis and Protein Solutions revenue rose 39% to $56.6 million, whilst NGS Applications revenue increased 12% to approximately $61.8 million. The company raised its fiscal 2026 revenue guidance to $456 million–$457 million, representing approximately 21% year-over-year growth at the midpoint. Gross margin improved to 52.8%, up 120 basis points sequentially. AI-enabled drug discovery emerged as a significant growth driver. Management expressed confidence in achieving triple-digit order growth in both fiscal 2026 and fiscal 2027. Twist reiterated its expectation to reach adjusted EBITDA breakeven in the fiscal fourth quarter. The company formally launched its Complex Genes offering after early-access customers ordered more than 1,800 constructs.

Yahoo Finance
Jun 19th, 2026
Twist Bioscience gains 153% as tech firms use DNA synthesis for AI genomic databases

Twist Bioscience Corporation has been highlighted as a top contributor by Osterweis Capital Management in its Q1 2026 investor letter. The synthetic DNA manufacturer closed at $87.56 per share on 18 June 2026, with a market capitalisation of $5.45 billion. The company, which produces synthetic genomic material for drug discovery and genomic testing, is positioned in the expanding liquid biopsy field. Notably, Twist is being used by technology companies as an outsourced laboratory for building genomic databases for AI large language models, a new growth area that contributed to strong Q1 performance. Twist's Q2 fiscal 2026 revenue reached $110.7 million, up over 19% year-on-year. Hedge fund holdings increased to 30 portfolios by end of Q1 2026, up from 24 the previous quarter.

Yahoo Finance
Jun 19th, 2026
Eli Lilly and Twist Bioscience use AI to accelerate drug development and growth

Eli Lilly and Twist Bioscience are leveraging AI to accelerate drug development, representing different opportunities in healthcare's AI evolution. Lilly, a pharmaceutical giant dating to the 1870s, is partnering with OpenAI and Nvidia on drug discovery and AI co-innovation labs. Trading near $1,120, Lilly shares have gained 36% over the past year and over 400% in five years. First-quarter 2026 revenue jumped 56% to $19.8 billion, whilst net income climbed 168% to $7.4 billion. The company's newly approved weight-loss pill, Foundayo, could significantly expand its patient base. Twist Bioscience, founded in 2013, produces synthetic DNA for pharmaceutical testing. Its shares trade around $83, up 136% over the past year, though down 26% over five years, presenting a higher-risk growth opportunity.